Avastin (bevacizumab) - Angiogenesis Inhibitor and Cancer Therapy
Avastin has become the first angiogenesis inhibitor to market; it secured US FDA approval at the end of February 2004 for use as a first-line treatment for patients with metastatic colorectal cancer.
